Genomics Group Leader,
Genomics and transcriptomics laboratory.
Tumors apparently identical at the microscopic observation can have entirely different clinical behaviors in terms of survival and response to treatment, on the basis of their specific molecular alterations.
The modern personalized medicine can arrest the progress of the disease by means of drugs able to target specific pathologically modified proteins.
The transformation of a population of cells from normal to tumor occurs gradually, through the progressive accumulation of several gene mutations transmitted from a mother cell to daughter cells.
Some of these modified genes give origin to proteins able to increase the proliferative ability of the cells, whereas others allow tumor cells to invade the near tissues and to colonize distant organs, causing the death of the patient.
As consequence of a progressive heterogeneity, tumor cells and molecules acquire specific abilities, but, like the different instruments in an orchestra, interplay in a highly regulated dialogue necessary to favor malignancy.
The genome/transcriptome of the tumor micro-environment, divided in its components, is essential for understanding progression to metastatic disease.
Understanding this evolution allows to develop new molecular targeted drugs and to optimize the actual therapeutic treatments.
Chiara Maria Mazzanti’s laboratory is involved in mapping the cellular networks perturbed during cancer progression by systematic, high-throughput, genome-wide analysis at both the DNA and mRNA level
Chiara Maria Mazzanti received from the University of Pisa her Master’s degree in Biological Sciences and her PhD in Experimental Oncology.
She spent many years abroad, at the Laboratory of Human Neurogenetics, NIAAA, NIH, Bethesda MD, USA, at the Advanced Technology Center National Cancer Institute of Health (NCI/NIH), and at the Laboratory of Human Cytogenetics, Cancer Research UK London Research Institute, London, UK.
Recently she got her Specialization in Clinical Pathology at the University of Pisa.